Teva Pharmaceutical (TEVA) Misses Q4 EPS by 1c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/17/2026
- Generac strikes $8B supply deal with Amazon for data center power
- Wall St ends lower after Fed hikes interest rates, sees more tightening ahead
- Paradium AI (PAAI) Halted, News Pending
- Shipping stocks on fire — but cracks are forming in the rate rally
- JPMorgan Fed scenario analysis: 5 paths for the S&P 500 today
Canaccord Genuity Downgrades Teva Pharma (TEVA) to Hold
February 8, 2013 7:17 AM ESTCanaccord Genuity downgraded Teva Pharma (NYSE: TEVA) from Buy to Hold with a price target of $45.00 (from $50.00) following Q4 results.
For an analyst ratings summary and ratings history on Teva Pharma... More
